Fig. 1From: Biomarker driven treatment of head and neck squamous cell cancerEGFR and receptor tyrosine kinase signaling in head and neck cancer. Resistance to EGFR inhibition may arise via signaling from redundant tyrosine kinases, such as HER family members, as well as downstream signaling activation. These may be important biomarkers predicting therapeutic response in head and neck cancerBack to article page